S-2

Synthesis of nitrodopamine hydrogensulfate (1)
A solution of dopamine hydrochloride (20 g, 105 mmol) and sodium nitrite (25 g, 362 mmol) in 600 mL water was cooled to 0°C using an ice bath. To this, an aqueous sulphuric acid (200 ml, 20 v/v%) was slowly added. After addition, the ice bath was removed and the solution was stirred overnight. The resulting dispersion was filtered and the collected solid was washed with icecold water and methanol and finally dried in vacuo to give nitrodopamine hydrogensulfate.
Yield: 15.6 g (50% 
16-hydroxy hexadec-6-enoic acid (2)
Potassium hydroxide (2.1 g, 37.4 mmol) and ω-hexadec-6-enlactone (6 g, 23.7 mmol) were dissolved in ethanol (75 mL). The solution was heated for 5 h at reflux and was then allowed to cool down and stand overnight. After concentrating the solution to about 25 mL, water (120 mL) was added and the solution was acidified with aqueous sulphuric acid (5 N). The resulting white precipitate was collected, washed 3 times with water (20 mL) and dried in vacuo to give product 2 in a yield of 5.92 g (92.4 %).
16-bromoisobutyroxy hexadec-6-enoic acid (3)
A solution of 16-hydroxy hexadec-6-enoic acid (2 g, 7.4 mmol), anhydrous pyridine (10.5 mL) and anhydrous THF (20 mL) was cooled in an ice bath to 0°C. 2-Bromo-2-methylpropionyl bromide (2.2 mL, 17.8 mmol) was slowly dropped into the mixture. After addition, the mixture was stirred for another hour at 0°C, and then 24 h at room temperature. The resulting mixture S-3 was diluted with ethyl acetate and extracted twice with hydrochloric acid (2 N) and water. The organic phase was dried with sodium sulfate, filtered and concentrated. Purification of the crude mixture was done by silica gel column chromatography using hexane/ethyl acetate 20/1 to 10/1 as eluent to give product 3 in a yield of 463 mg (15%). 
16-bromoisobutyroxy hexadec-6-enoic acid (2'-(3',4'-Dihydroxy-6'-nitrophenyl))ethylamide (4)
Compound 3 (180 mg, 0.43 mmol) and N-hydroxysuccinimde (66 mg, 0.57 mmol) were dissolved in a mixture of anhydrous dioxane (1 mL) and anhydrous ethyl acetate (1 mL). After cooling to 0°C, dicyclohexyl carbodiimide (DCC) (88 mg, 0.43 mmol) was added and the resulting solution was stirred for further 5 min at 0°C and then overnight at room temperature.
The solution was diluted with ethyl acetate, filtered and concentrated. The residue was taken up in dichloromethane and was washed with sodium hydrogencarbonate solution (5 wt%, 10 mL) and water (3 x10 mL). The organic phase was dried with sodium sulfate, filtered and concentrated. 6-nitrodopamine hydrogensulfate (81 mg), triethylamine (0.14 mL) and anhydrous DMF were added to the so-obtained crude NHS-activated acid (166 mg). The resulting solution was stirred for 24 h. The solution was acidified with a few drops of hydrochloric acid (2 N), diluted with dichloromethane, and washed with hydrochloric acid (2 N), water and brine. After drying over sodium sulfate, the organic phase was filtered, and concentrated to give the nitrocatechol modified initiator 4 (90 mg, initiator 60% of initiator carries catechol moiety). 
Preparation of initiator particles
As synthesized oleate capped particles (490 mg, 5.6 nm core diameter) and initiator 4 (90 mg)
were dispersed in 5 mL dry DMF (initiator/nm 2 nanoparticle surface ~3/1, initiator 60% catechol moiety). The solution was sonicated for 1h, shaken for 24 h and sonicated again for 1h. The nanoparticle solution was then dropped into ethanol and the resulting precipitate was collected by centrifugation. The collected product was washed twice with ethanol, transferred with water into a flask and freeze dried to give 38 mg initiator particles (organic fraction 59 %). 
